Clinical Trial Update: Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 randomized dose-escalation trial of sorafenib in patients with previously untreated metastatic renal cell carcinoma. The study was terminated and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Accelerated Community Oncology Research Network | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2013-07-18